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Perspective on Biorepository Return of 
Results and Incidental Findings 
Scott D. Jewell* 
INTRODUCTION 
Biorepositories and biobanking have gained considerable 
momentum in recent years.1 Biorepositories consist of collec-
tions of biospecimens for science venues that rely on specimens 
for analysis.2 The number and kinds of biorepositories would be 
too numerous to list. However, the growing membership of or-
ganized societies such as the International Society of Biological 
and Environmental Repositories (ISBER),3 the Biobanking and 
Biospecimen Resources Research Infrastructure,4 the Public 
Population Project in Genomics,5 the European, Middle East-
ern, and African Society for Biopreservation and Biobanking,6 
the Canadian Tumour Repository Network,7 and the National 
                                                          
© 2012 Scott D. Jewell 
 *  Ph.D., Deputy Director for Research Resources, and Professor and Di-
rector, Program for Biospecimen Science, Van Andel Research Institute, 
Grand Rapids, Michigan. Preparation of this article was supported by the Na-
tional Institutes of Health (NIH), National Human Genome Research Institute 
(NHGRI) grant #2-R01-HG003178 on “Managing Incidental Findings and Re-
search Results in Genomic Biobanks & Archives” (Wolf, PI; Kahn, Lawrenz, 
Van Ness, Co-Is). The contents of this article are solely the responsibility of 
the author(s) and do not necessarily represent the views of NIH or NHGRI. 
 1. See, e.g., Alice Park, Biobanks, TIME, Mar. 23, 2009, at 63. 
 2. See id. (“Think of it as an organic bank account. You put your bio-
material in and earn medical interest in the form of knowledge and therapies 
that grow out of that deposit . . . .”). 
 3. INT’L SOC’Y FOR BIOLOGICAL & ENVTL. REPOSITORIES, 
http://www.isber.org (last visited Mar. 24, 2012). 
 4. BIOBANKING & BIOMOLECULAR RESOURCES RES. INFRASTRUCTURE, 
http://www.bbmri.eu (last visited Mar. 24, 2012). 
 5. PUB. POPULATION PROJECT GENOMICS, http://www.p3g.org (last visit-
ed Mar. 24, 2012). 
 6. EUR., MIDDLE EASTERN & AFR. SOC’Y FOR BIOPRESERVATION & 
BIOBANKING, http://www.esbb.org (last visited Mar. 24, 2012). 
 7. CANADIAN TUMOUR REPOSITORY NETWORK, http://www.ctrnet.ca (last 
visited Mar. 24, 2012). 
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Cancer Institute’s (NCI) Office of Biorepositories and 
Biospecimen Research (OBBR)8 demonstrates worldwide inter-
est and energy in the development of best practices and exper-
tise in biobanking. One accepted definition of the term “reposi-
tory” is ISBER’s definition: “A repository is defined as an entity 
that receives, stores, processes and / or disseminates specimens 
. . . . It encompasses the physical location as well as the full 
range of activities associated with its operation.”9 Another defi-
nition comes from the Department of Health and Human Ser-
vices’ Office for Protection from Research Risks: “Human Tis-
sue Repositories collect, store, and distribute human tissue 
materials for research purposes. Repository activities involve 
three components: (i) the collectors of tissue samples; (ii) the 
repository storage and data management center; and (iii) the 
recipient investigators.”10 
Repositories of human biospecimens have rapidly devel-
oped to meet the demand for biospecimens—from individuals 
afflicted with diseases—for use in intense and competitive re-
search initiatives seeking to discover new knowledge in the ge-
nomic era.11 The increasing value and interest in human 
biorepositories have elevated concerns for human subjects as 
well as ethical issues related to the collection, holding, and use 
of biospecimens, especially where biospecimens may be used for 
future undefined research.12 Furthermore, advancements in 
technology are more likely to prove the assumption that a deep 
interrogation into new knowledge could provide actionable 
medical treatments, such as directly targeting a biological 
pathway using an existing drug or intervention treatment that 
may have significance for future individual health outcomes. 
                                                          
 8. NAT’L CANCER INST., OFF. BIOREPOSITORIES & BIOSPECIMEN RES., 
http://www.biospecimens.cancer.gov/default.asp (last visited Mar. 24, 2012). 
 9. Int’l Soc’y for Biological & Envtl. Repositories, 2008 Best Practices for 
Repositories: Collection, Storage, Retrieval and Distribution of Biological Ma-
terials for Research, 6 CELL PRESERVATION TECH. 5, 10 (2008). 
 10. Office for Prot. from Research Risks, Issues to Consider in the Re-
search Use of Stored Data or Tissues, U.S. DEP’T OF HEALTH & HUMAN SERVS. 
(Nov. 7, 1997), http://www.hhs.gov/ohrp/policy/reposit.html. 
 11. See Park, supra note 1. 
 12. Nils Homer et al., Resolving Individuals Contributing Trace Amounts 
of DNA to Highly Complex Mixtures Using High-Density SNP Genotyping Mi-
croarrays. PLOS GENETICS 9 (Aug. 2008), available at 
http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1
000167. 
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Therefore, the research use of biospecimens from 
biorepositories—often well removed from the direct care of pa-
tients—has become an ethical concern when considering the 
potential benefits to patients and has opened a debate over the 
return of research results to individuals.13 Research results can 
include: 1) known events of importance such as the discovery of 
inheritable genes associated with increased managed 
healthcare for an individual or their family members;14 2) pri-
mary results of unknown significance, such as a finding of new 
data or information generated from research testing that may 
affect some element of healthcare;15 and 3) secondary research 
findings such as mistakes uncovered in the management of re-
search material (e.g., a discordant pathological diagnosis) that 
may or may not have a further effect on the healthcare of an 
individual.16 In these situations, the delivery of the data or in-
formation would include thorough reviews by scientists and 
physicians with appropriate knowledge to weigh the im-
portance of the effectiveness of the research results. It should 
be noted that there is a systematic process that must occur be-
tween the generation of well-controlled and documented re-
search results and the final determination of accurate meas-
urement and validation to determine the usefulness of results 
for patient care. Laboratory tests for patient care are controlled 
                                                          
 13. See, e.g., OFFICE OF BIOREPOSITORIES & BIOSPECIMEN RESEARCH, 
NAT’L CANCER INST., & NAT’L INSTS. OF HEALTH, WORKSHOP ON RELEASE OF 
RESEARCH RESULTS TO PARTICIPANTS IN BIOSPECIMEN STUDIES: WORKSHOP 
SUMMARY 3 (2011) [hereinafter WORKSHOP SUMMARY], available at 
http://biospecimens.cancer.gov/global/pdfs/NCI_Return_Research_Results_Su
mmary_Final-508.pdf (“Proponents of sharing research results contend that 
human research participants should have the option of receiving potentially 
valuable information. Opponents maintain that the purpose of research is to 
generate general knowledge rather than individual data, and that research 
laboratories are not necessarily held to the same standards as clinical labora-
tories.”); Laura M. Beskow & Wylie Burke, Offering Individual Genetic Re-
search Results: Context Matters, 2 SCI. TRANSLATIONAL MED., June 30, 2010, 
at 1; Laura M. Beskow & Sondra J. Smolek, Prospective Biorepository Partici-
pants’ Perspectives on Access to Research Results, 4 J. EMPIRICAL RES. ON 
HUM. RES. ETHICS, Sept. 2009, at 99, 99. 
 14. E.g., Beskow & Burke, supra note 13, at 1–2. 
 15. E.g., Lynn G. Dressler, Biobanking and Disclosure of Research Re-
sults: Addressing the Tension Between Professional Boundaries and Moral In-
tuition, in THE ETHICS OF RESEARCH BIOBANKING 85, 89 (J.H. Solbakk et al. 
eds., 2009). 
 16. E.g., Marianna J. Bledsoe et al., Practical Implementation Issues and 
Challenges for Biobanks in the Return of Individual Research Results, 14 
GENETICS MED. 478, 482 (2012). 
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and managed in the United States by the Clinical Laboratory 
Improvement Amendments (CLIA).17 
A number of concerns surrounding the return of results ex-
ist, several of which are not directly covered through the in-
volvement of biorepositories. Individuals should have the op-
portunity to determine if their biospecimens can be used in 
research. The informed consent process is the best point to re-
ceive approval for the intended uses, broad or narrow, and to 
discuss the issues surrounding research results. It is unlikely 
that all uses and results can be defined. Even though there is a 
very small risk of having an individual’s identity breached by 
non-approved users, many researchers prefer receiving 
biospecimens designated to be non-human subjects, which 
means having no identity or reasonable connection to the pa-
tient.18 Thus if an attempt to return research results did occur, 
the biorepository would not be able to provide certainty for the 
chain-of-custody (CoC) of the biospecimen to the individual’s 
identity, which is purposefully broken in de-identification pro-
cesses. The complexity of this process is easiest to explain to an 
individual by indicating that research results will not be re-
turned. 
A result from research that could carry an ethical justifica-
tion to re-match the biospecimen to an individual would be one 
of a known inheritable genetic condition of significant 
healthcare management—especially if the individual was not 
already aware of the genetic inheritance.19 Even under these 
circumstances the use and availability of the results, compared 
to when the biospecimens were collected, need to be weighed 
against the value of communicating the information to an indi-
vidual. The existing or monitoring institutional review boards 
(IRBs)20 are already generally capable of determining the value 
of returning the results without further changes in the ethical 
or human-subjects standards. 
Return of research results could also be considered based 
on the type of biorepository that manages the biospecimens. 
                                                          
 17. See 42 C.F.R. § 493 (2011). 
 18. See Amy L. McGuire & Richard A. Gibbs, No Longer De-Identified, 312 
SCIENCE 370, 370 (2006) (“At present, ethical concerns about the privacy of 
subjects whose sequenced DNA is publicly released have largely been ad-
dressed by ensuring that the data are ‘de-identified’ . . . .”). 
 19. See, e.g., Dressler, supra note 15, at 93–94. 
 20. 45 C.F.R. § 46.109 (2011). 
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There is not a one-size-fits-all category for biorepositories, and 
thus special consideration could be given to biorepositories that 
can meet the demands for the CoC. The infrastructure and 
management of biorepositories that can meet the demands to 
maintain ethical connectivity to research results would differ 
from the general biorepository and would certainly cost more to 
operate. Funding challenges would exist for these types of 
biorepositories and, like the funding models for clinical labora-
tories, these costs would need to be considered as part of the 
healthcare provided to patients. 
Issues and concerns surrounding the return of research re-
sults as defined above are further discussed from the 
biorepository point of view below. Biospecimens held in 
biorepositories have been used for decades to generate research 
results. Then and now the policies on the return of research re-
sults have always sounded a clear “no” because research results 
by their nature have not been validated or proved meaningful 
or actionable in a clinical setting.21 The issue of return of re-
sults is a relatively new debate compared to the decades of ex-
istence of human biorepositories,22 yet when a transition from 
research to clinical action has occurred, significant time, effort, 
and testing have been needed to derive a meaningful data set 
for clinical action. The impetus for this rising debate is due to 
capabilities of genomic technology, the potential that genomic 
information can be linked to an individual, and the fact that 
genomic signatures may determine, predict, or direct treatment 
for health outcomes. Features of biorepositories that play an 
important role when results are returned include: biorepository 
structure and function, informed consent, CoC, IRB standards 
and decision-making, quality management programs (QMPs), 
funding, quality controls, proficiency testing, technologist certi-
fication, biorepository accreditation,23 CLIA certification,24 risk 
and disaster planning, and insurance. To ensure the proper and 
ethical return of research results to an individual, a 
biorepository should be held to the same standards that are in 
                                                          
 21. See Dressler, supra note 15, at 91. 
 22. WORKSHOP SUMMARY, supra note 13, at 8 (“Although these issues 
have been in the public consciousness since the 1980s, interest has multiplied 
in recent years.”). 
 23. See CAP Accreditation for Biorepositories, C. AM. PATHOLOGISTS 
(2011), http://www.cap.org/apps/docs/laboratory_accreditation/lap_info/bio_bro 
chure_042011.pdf. 
 24. See WORKSHOP SUMMARY, supra note 13, at 8–9. 
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place for clinical testing. 
I. BIOREPOSITORY STRUCTURE AND FUNCTION 
The complexity and breadth of the functions and services 
in human biorepositories make it difficult to apply prescribed 
requirements across the board. To appreciate the complexity of 
providing return of results, it is important to understand the 
basics of the structure and function of biorepositories. Human 
biorepository structures range from the individual investigator-
managed biorepositories that may contain a few hundred 
biospecimens to large well-managed biorepositories with thou-
sands to millions of biospecimens.25 The operating premise for 
these biorepositories range from single user with minimal doc-
umentation and relatively low value to high-profile drug, de-
vice, or clinical trials with associated data and documentation 
of relative high cost and value.26 Until recently, with the for-
mation of biobanking societies and government influence on 
improved quality of research resources, the infrastructure and 
management of biorepositories could be considered haphazard 
at best.27 While there are excellently managed, well-funded 
biorepositories that espouse the ability to move into the clinical 
translational space, suggesting that the return of research re-
sults is possible for biorepositories, as a broad based general 
concept it is impracticable. Biorepository structure and function 
are generally not funded well enough.28 Requiring broad-based 
programs to get approval before returning research results 
would be an unfunded mandate on a system that has no meth-
od to force increases in revenue.29 The result would be an action 
                                                          
 25. See Donating Tissue for Cancer Research: Biospecimens and 
Biorepositories, NAT’L CANCER INST., http://www.cancer.gov/ 
cancertopics/factsheet/Information/donating-tissue-research (last visited Apr. 
4, 2012) (stating that the size of biorepositories varies greatly across the in-
dustry). 
 26. See id. 
 27. See Nat’l Cancer Inst., Overview, OFF. BIOREPOSITORIES & 
BIOSPECIMEN RES., http://biospecimens.cancer.gov/about/overview.asp (last 
visited Apr. 4, 2012) (stating that a primary purpose of the OBBR is to bring 
order to a haphazard system). 
 28. Gary E. Goodman, Biorepositories: Let’s Not Lose What We Have So 
Carefully Gathered!, 15 CANCER EPIDEMIOLOGY, BIOMARKERS, & PREVENTION 
599, 599 (2006) (citing a lack of stable funding as a major shortfall of many 
biorepositories). 
 29. See id. (noting that most biorepository funding occurs on a trial-by-
trial grant basis). 
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that can’t be implemented without significant funding. It 
makes more sense to determine the interest and scope of 
biorepositories that can enter the space of translational medi-
cine with intent to return results to individuals and then set 
requirements for those biorepositories to meet the appropriate 
standards. Biorepositories establishing best practices are work-
ing towards preventing errors in transcription, building robust 
information systems to manage the inventory, improving quali-
ty control and quality assurance procedures, creating manage-
ment and backup processes for freezers and other equipment, 
ensuring the safety of technologists, documenting standard op-
erating procedures, making appropriate decisions in distribu-
tion and regulatory requirements, and managing a host of oth-
er subtle issues that arise in running a biorepository.30 The 
varying structures and complexities of biorepositories raise the 
awareness that standardization is both important and neces-
sary to provide return of results. However, the CoC could be 
very problematic. Some biorepositories do carry the protected 
health information (PHI) of the patient and connectivity to the 
biospecimens. This doesn’t mean the standard operating proce-
dures maintain CoC, but it does make the process possible. 
However, many biorepositories do not store or maintain PHI.31 
Under these circumstances if the use of biospecimens produces 
significant findings, identification practices would be difficult to 
connect with certainty to an individual who donated the 
biospecimen for research. To judge if a biorepository is aligned 
and able to manage the return of results, both internal and ex-
ternal adjudication of its operation should be implemented. The 
responsibility to individuals to provide research results is a se-
rious undertaking, which demands fool-proof processes and 
procedures to connect with certainty the research data to the 
identity of an individual. 
                                                          
 30. E.g., Walter C. Bell et al., Organizational Issues in Providing High-
Quality Human Tissues and Clinical Information for the Support of Biomedi-
cal Research, 576 Methods Molecular Biology 1, 1–28 (2010); Samir N. Khleif 
et al., AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: 
Advancing the Use of Biomarkers in Cancer Drug Development, 16 CLINICAL 
CANCER RES. 3299, 3302 (2010); Brian R. Leyland-Jones et al., Recommenda-
tions for Collection and Handling of Specimens from Group Breast Cancer 
Clinical Trials, 26 J. CLINICAL ONCOLOGY 5638, 5639–41 (2008). 
 31. E.g., Privacy, ORBIT, http://www.aurorahealthcare.org/services/orbit/ 
bg.html (click on the “Privacy” tab at the top of the page) (last visited Apr. 4, 
2012). 
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A. INFORMED CONSENT, CHAIN OF CUSTODY, AND IRB 
STANDARDS AND DECISION MAKING 
Biorepositories may receive patient-consented 
biospecimens but without holding the patient identifiable in-
formation. In these situations the clinical site would hold the 
patient’s identifying documentation. The associated IRB proto-
col may or may not allow reconnection to the patient’s identity. 
In some biorepositories the biospecimen collections may exist 
with complete anonymity of the origin of the person who con-
tributed the biospecimens. Thus not all biorepositories would 
be able to return results to individuals without the appropriate 
CoC or an IRB approval or consent to re-connect to an individ-
ual.  
Assuming that consent from all patients will be required, 
the identifiability of a patient may not be a jurisdiction of the 
biorepository and the processes to maintain CoC would be 
needed for every patient set of biospecimens while the recon-
nection event will be rare. To maintain this functionality would 
be very costly to the biobanking and research enterprise.  
 Bioinventory software is also a key element in the safe-
guard of the CoC. Several choices in software selection exist, 
but the costs range from inexpensive homegrown products to 
commercial products costing several thousands of dollars, and 
enterprise systems costing hundreds of thousands of dollars.32 
Reliable options that include complete auditing transaction 
systems to manage CoC and security for the protection of hu-
man subjects information would be required if return-of-results 
programs are implemented. Surprisingly, many software 
bioinventory systems do provide these defaults, but again the 
often-missing link is the connecting data to the link to an indi-
vidual’s identity.  
 A confounding issue in the return of results involves the 
authority of the IRB, which would have approved the consent to 
collect biospecimens. If there is a decision to return results, 
which is then managed under CLIA law, who makes the deci-
sion to return results to the individual? How is this decision 
                                                          
 32. E.g., The Multiple Myeloma Research Foundation (MMRF) and Trans-
lational Genomics Research Institute (TGen) Announce Innovative Molecular 
Profiling and Biobanking Collaboration for Landmark Multiple Myeloma 
Study, TRANSLATIONAL GENOMICS RES. INST. (Apr. 2, 2012), 
http://www.tgen.org/news/index.cfm?newsid=2055 (announcing the use of 
VARI/TGen Bioinventory software). 
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made? Qualified individuals who have the appropriate ability 
and authorization should make these decisions. This brings an 
additional burden on the IRB and requires that the IRB be 
made up of individuals who are both well versed in the protec-
tion of human subjects but also are able to assess the clinical 
significance of the reported data. CLIA is clearly a requirement 
and the process on the engagement of CLIA-licensed assay re-
porting is well known, but the decision and criteria for moving 
a research result to a clinical event is not defined and would 
require a separate body of specialists. 
B. QUALITY MANAGEMENT PROGRAMS 
Technological advancements have put a greater emphasis 
on the quality of biospecimens since the resulting data from 
these improved sensitivities have been to shown to be problem-
atic if not conducted using an appropriate biospecimen—such 
as seen with the development of an RNA measurement or RNA 
integrity number value.33 Thus the improvements in the man-
agement of biospecimens for both collection and storage have 
focused on quality assurance and quality control procedures.34 
Clinical trial groups of the NCI sponsor a cooperative group-
banking committee tasked with harmonizing procedures and, 
where possible, documenting measures of quality control and 
management of these biospecimens.35 While efforts to improve 
quality, or least the documentation to assess or point to a 
measure or degree of quality, are ongoing using the 
Biospecimen Reporting for Improved Study Quality stand-
ards,36 very few biorepositories in academia, especially those 
with minimal resources, fully implement a QMP. These pro-
grams are modeled after groups that maintain good laboratory 
or manufacturing practice, such as is used in handling pharma-
ceutical-grade compounds. These programs are costly, but they 
easily point out where mistakes are made in an operation and 
enforce the necessary changes to improve the procedure, pro-
                                                          
 33. See How the RNA Integrity Number (RIN) Works, AGILENT TECH. 
(June 2004), http://www.agilent.com/about/newsroom/lsca/background/ 
rna_integrity.pdf. 
 34. See Leyland-Jones, supra note 30, at 5639. 
 35. Cooperative Group Banks, Quality Assurance, NAT’L CANCER INST., 
http://cgb.cancer.gov/biospecimens/qualityassurance.html (last viewed Apr. 11, 
2012). 
 36. See Helen M. Moore et.al., Biospecimen Reporting for Improved Study 
Quality, 9 BIOPRESERVATION & BIOBANKING 57, 58–59 (2011). 
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cess, and ultimately the product. In the biorepository the prod-
uct is the identity, quality, and correct biospecimen. In the clin-
ical setting the combination of CLIA, an accreditation review 
like the American College of Pathologists (CAP),37 and the la-
boratories internal quality management review team provides 
the level of scrutiny and oversight to enforce corrective action 
plans. The biorepository with research biospecimen inventory 
should also be required to meet the stringency of assurance. 
Again the QMP can be a significant consumer of the operating 
cost of a biorepository with research biospecimens that are 
simply too large to be managed at this present state of funding 
for biorepositories.38 
C. FUNDING 
A well-funded biorepository can implement provisions of 
tracking and managing biospecimens into and out of the 
biorepository. However, in general, biorepositories are funded 
at a minimal operational level even if the biorepository has sig-
nificant value, standards, and diverse services.39 Greater than 
average funding is needed to maintain a system with sufficient 
numbers of well-trained operating personnel as well as equip-
ment and software systems for biorepository inventory and 
management. While software systems and the implementation 
of operation activities such as the use of barcodes have im-
proved significantly, many biorepositories still function with 
homegrown software systems and manual operating proce-
dures. A system that would implement the standards and pro-
cesses discussed above for the return of research results would 
require significantly more operating funding to manage the po-
tential to provide this level of service.40 Return of research re-
sults or incidental findings and thus the need to connect back 
to the patient would most probably be a rare event. However, 
                                                          
 37. See CAP Accreditation for Biorepositories, supra note 23. 
 38. See Goodman, supra note 28, at 599. 
 39. See, e.g., Geoffrey S. Ginsburg et al., Centralized Biorepositories for 
Genetic and Genomic Research, 299 JAMA 1359, 1359 (2008) (noting that in-
stitutions often have “limited resources and inconsistent funding”). 
 40. Bledsoe, supra note 16, at 480 (“Setting up systems to return individ-
ual research results has infrastructure implications and costs, including the 
need to set up systems for decision-making and processes for implementing 
the return of findings, staffing and funding for recontact, informatics systems 
for reporting and auditing and tracking of specimens, etc.”). 
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the expense to maintain the procedures to provide this service 
with CoC assurance would be significant to the operational 
funding for the average biorepository. 
D. QUALITY CONTROLS, CERTIFICATION, AND PROFICIENCY 
New technology purposes to provide more detailed insights 
into the molecular signatures of biological systems. In turn, 
these technologies will also provide increased sensitivities and 
a greater demand on the quality of procurement and manage-
ment of biospecimens that are used in the generation of re-
search data. Biobanking organizations are central drivers in ef-
forts to improve the accuracy and stringencies in the practices 
of biorepositories and to ensure that biological and environ-
mental resources provide the best services.41 At present, 
biorepositories self-measure quality control because profession-
al services to administer these activities are not implemented. 
One assessment of self-certification is to arrange both internal 
and external reviews of the biorepository operations to certify 
high standards of operation. Proficiency analysis is an im-
portant measure of laboratory procedures such as the isolation 
of nucleic acids to qualify procedures and routine consistency 
and accuracy in assay performance. Certification of technolo-
gists is another indicator of competency in operations. These 
proficiency and certification measures, coupled with internal 
and external reviews, ensure vetted processes to manage re-
turn of research results. 
E. ACCREDITATION AND CLIA 
Biobanking is not a new phenomenon across scientific dis-
ciplines, yet the focus of increased interest and improvements 
in the practices of biorepositories is directly related to the ad-
vancements in analytical genomic technology.42 Unfortunately 
a standard to ensure research biorepositories are well managed 
and controlled to meet the rigor of clinical reporting require-
ments has never been a goal.43 Beyond the biorepository quality 
control, proficiencies, and technologist certifications, the most 
important achievements would be accreditation and a license 
under the CLIA. As noted above, a CLIA license is the re-
                                                          
 41. See, e.g., Int’l Soc’y for Biological & Envtl. Repositories, supra note 9 
(outlining best practices to improve sample quality). 
 42. See Ginsburg, supra note 39, at 1359. 
 43. See Bledsoe, supra note 16, at 479–80. 
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quirement to be able to return results to individuals.44 Move-
ment to develop biorepositories that qualify for the stringent 
requirements of CLIA is nowhere more evident than in the 
CAP’s plan to launch a Biorepository Accreditation Program 
(BAP) in 2012.45 While the initial phases of the CAP BAP pro-
gram will not provide biorepositories with an approach to CLIA 
accreditation, it is very significant because the majority of CAP 
accreditation programs validate the consistent quality of 
biospecimen.46 Given time for the CAP’s BAP program to ma-
ture, and good actionable reasoning to return results, 
biorepositories may become involved in the clinical space, and 
the CLIA application will then apply in some areas of 
biobanking. Although proficiency, certification, and quality con-
trol are important working elements in biobanking, accredita-
tion and CLIA license are the documents that must be in place 
to pave the road for return of research results. 
F. RISK, DISASTER PLANNING, AND INSURANCE 
Return of research results places an expectation that, 
when individual’s biospecimens are stored, not only will the 
biospecimens be used in initial research to generate data, but 
that remainder aliquots of biospecimens could also be used to 
generate more data. With each data generation potentially end-
ing in a process that could qualify for the return of results to 
individuals, risk attributed to mismanagement is heightened.47 
In a similar context, liability and insurance costs for a 
biorepository may result or increase if reporting errors were a 
consequence of mismanagement by the biorepository that could 
affect the health decisions of an individual. In addition, if the 
perception of increased value of the biorepository contents and 
risk increase, the biorepository’s institution will need to carry a 
larger insurance coverage in case of disasters that result in the 
loss of the contents. Presently most biorepositories likely have 
emergency planning for the common freezer failure. Emergen-
cies can be classified as a more minor single event that can be 
handled by the biorepository personnel. However, disasters are 
                                                          
 44. See supra INTRODUCTION. 
 45. See CAP Accreditation for Biorepositories, supra note 23. 
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events that can jeopardize or destroy a large portion or an en-
tire biorepository such as building structure failure or major 
damage due to natural disasters or fire. Insurance coverage 
needs to cover the perceived value of a biorepository collection. 
However, including insurance coverage to manage return of re-
sults represents a new cost to the risk management of the      
biorepository in order to manage both the potential loss of the 
biospecimens and any lawsuits from individuals. 
CONCLUSION 
Return of research results to individuals when an actiona-
ble discovery has been found does have an ethical consideration 
that should be discussed and, where possible, implemented. 
However, at this time, the state of biobanking as outlined above 
points to many gaps in a system that is not applicable for clini-
cal settings or the corollary that is the return of results. Alt-
hough a developing accreditation program from CAP48 and a 
proficiency program49 started by ISBER and the International 
BioBank of Luxembourg bring documented standards for 
biorepositories, the lack of CLIA license, which is required for 
the return of results, continues to be a significant deficit in the 
credibility of biorepositories to perform and manage that activi-
ty. Regardless of the accreditation and license structural pro-
cesses that, in time, could be managed by a few biorepositories 
that want to function in that space, other operational issues to 
provide the functionality needed to accomplish the return of re-
sults will need to be met. These include funding, long-term risk 
management, and insurance. Furthermore, if funding and risk 
management solutions existed to develop and operate the infra-
structure to return research results, the most significant issue 
that remains is the validation of research findings in the con-
text of the meaningfulness to an individual’s healthcare. Prior 
to enacting policies or requirements to return research results 
guidelines should be established on the healthcare benefits and 
appropriateness of the results. 
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